BIT225 is an experimental drug candidate under development by Biotron Limited for use in the treatment of both HIV and hepatitis C infection. By blocking Vpu ion channel activity, it disrupts HIV assembly within host monocyte cells; its method of action is a first for HIV drugs.[1] Because it targets replication in monocyte derived macrophages, it offers promise for treatment of viral reservoirs that are unaffected by standard treatments.[2] The activity of BIT225 is post-virus integration, with no direct effects on the HIV enzymes reverse transcriptase and protease.[3] Since Vpu ion channel activity is highly conserved, the virus is unlikely to become resistant via generation of Vpu ion-independent virus. In addition, the drug also has been credited with curing hepatitis C after 12 weeks of treatment.[4]

References

  1. ^ BIT225 therapy reduces HIV-1 burden in monocyte cells and decreases immune activation
  2. ^ BIT225, a Novel Assembly Inhibitor, Cuts HIV Load in Monocyte Reservoir
  3. ^ Antiviral Efficacy of the Novel Compound BIT225 against HIV-1 Release from Human Macrophages
  4. ^ BIT225 Trial Results Show Effective Cure of Hepatitis C
Allikas: https://en.wikipedia.org/wiki/BIT225
No tags for this post.